Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

Stumpe, Klaus O.; Ludwig, Malte

doi:10.1038/sj.jhh.1001395

Cited by 53 publications

(55 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…5 The present study sought to assess the antihypertensive efficacy and goal BP attainment rate with the recommended starting dose of olmesartan medoxomil, compared with that of the most widely prescribed antihypertensive agent, amlodipine. Although other ARBs have been compared with amlodipine in clinical trials, [20][21][22][23] the studies focused primarily on the absolute reduction in BP between the two agents and not on their ability to achieve a specific BP goal.…”

Section: Discussionmentioning

confidence: 99%

“…4 Olmesartan medoxomil has exhibited antihypertensive efficacy that compares favourably with that of atenolol, captopril, felodipine, and the ARBs losartan potassium (losartan), valsartan, and irbesartan in randomized, doubleblind, head-to-head comparative trials. [5][6][7] The present study was conducted to compare the efficacy and safety of the starting doses of olmesartan medoxomil and amlodipine besylate (amlodipine), currently the most widely prescribed antihypertensive agent, in patients with mild-to-moderate hyper-tension, as well as to compare the BP control rates achieved by olmesartan medoxomil and amlodipine. These data are useful in order to provide clinicians with information on alternative therapeutic regimens in the treatment of hypertension.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Chrysant

Marbury

Robinson³

2003

J Hum Hypertens

View full text Add to dashboard Cite

The antihypertensive efficacy of the angiotensin II receptor blocker olmesartan medoxomil has been shown to compare favourably with that of other antihypertensive agents. This randomized, double-blind study compared the antihypertensive efficacy of the starting dose of olmesartan medoxomil with that of the calcium channel blocker amlodipine besylate (amlodipine) in subjects with mild-to-moderate hypertension. Following a 4-week, single-blind, placebo run-in period, 440 subjects aged X18 years were randomized to the starting dose of olmesartan medoxomil (20 mg/day), amlodipine (5 mg/day), or placebo for 8 weeks. Subjects were evaluated by 24-h ambulatory blood pressure monitoring (ABPM) and by seated cuff blood pressure (BP) measurements at trough. The primary end point was the change from baseline in mean 24-h diastolic blood pressure (DBP) by ABPM at Week 8. Secondary end points included change from baseline in mean 24-h ambulatory systolic blood pressure (SBP) at 8 weeks, change from baseline in mean seated trough cuff DBP and SBP measurements, and response and control rates for DBP o90 and o85 mmHg. Control rates for SBP o140 and o130 mmHg were also calculated. Olmesartan medoxomil and amlodipine produced significantly greater reductions in ambulatory and seated DBP and SBP compared with placebo. Mean reductions in ambulatory and seated BP were similar between the two active agents; however, in the olmesartan medoxomil group, significantly more patients achieved the SBP goal of o130 mmHg and the DBP goal of o85 mmHg. Both drugs were well tolerated at the recommended starting dose. Although amlodipine was associated with a higher incidence of oedema, this did not reach statistical significance. Olmesartan medoxomil is an effective antihypertensive agent, with BPlowering efficacy at the starting dose similar to that of amlodipine, and is associated with more patients achieving the rigorous BP goals of SBP o130 mmHg and DBP o85 mmHg.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Chrysant

Marbury

Robinson³

2003

J Hum Hypertens

View full text Add to dashboard Cite

show abstract

“…Among ARBs, olmesartan selectively inhibits Ang II binding to Ang II subtype 1 (AT1) receptors with high potency and affords satisfactory BP control in monotherapy with a good tolerability profile (20)(21)(22)(23). Its combination with hydrochlorothiazide (HCTZ) has been shown to provide better 24-h BP control than monotherapy in patients with mild-to-moderate as well as in those with severe hypertension (24,25).…”

Section: Introductionmentioning

confidence: 99%

Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus

et al. 2008

View full text Add to dashboard Cite

“…In another study by Stumpe et al, 7 381 patients with MSDBP 100-120 mm Hg were randomised to olmesartan medoxomil 20 mg/day, or felodipine 5 mg/day. Both drugs lowered the MSDBP/MSSBP to the same degree.…”

Section: Active Comparative Studiesmentioning

confidence: 99%

“…In several randomised placebo-controlled studies, olmesartan medoxomil has demonstrated significant antihypertensive effects compared to placebo. 1,2 In other comparative studies, olmesartan medoxomil showed similar blood pressure (BP) lowering efficacy with angiotensin converting enzyme (ACE) inhibitors, calcium channel blockers, b-blockers and diuretics, [3][4][5][6][7][8][9] but superior antihypertensive potency against other ARBs given in equivalent starting doses. [10][11][12][13] In other studies, olmesartan medoxomil given in the highest recommended daily doses, its antihypertensive effect was similar to other ARBs.…”

Section: Introductionmentioning

confidence: 98%

Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update

2007

View full text Add to dashboard Cite

Olmesartan medoxomil is an angiotensin II (Ang II) receptor blocker (ARB) that has been approved by the US Food and Drug Administration (FDA) for the treatment of hypertension. It is a prodrug that is hydrolysed in the gut into its active metabolite, olmesartan (RNH-6270). Olmesartan is highly selective for the Ang II type 1 receptor (AT1) to which it binds completely and insurmountably and has very little affinity for the other receptor subtypes AT2 and AT4. After oral administration, in animals and humans, it achieves a maximal blood drug concentration within a maximal time of approximately 2 h. It is then slowly eliminated in the urine and faeces. His half-life is approximately 13 h, which makes it suitable for once-daily administration. Olmesartan medoxomil given orally in single daily doses of 20-40 mg has demonstrated significant blood pressure (BP) lowering effects in hypertensive patients. A medline search for the preparation of this manuscript was conducted and revealed 128 references, from 2000 to 2007. Of these, only 16 well-designed prospective clinical trials were selected. The remaining were either animal studies, reviews or studies in progress. In well-designed clinical trials, olmesartan medoxomil has demonstrated similar antihypertensive actions to the other antihypertensive drugs, as well as other members of its class given the highest recommended doses. In addition, the BP lowering effect of olmesartan, like the other members of its class, is greatly enhanced in combination with a diuretic. Its safety profile is similar to the other ARBs and no different than placebo.

show abstract

Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs

Abstract: The therapeutic profile of olmesartan medoxomil, which is a recently developed angiotensin II (A II)

Cited by 53 publications

References 13 publications

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension

Effects of Manidipine/Delapril versus Olmesartan/Hydrochlorothiazide Combination Therapy in Elderly Hypertensive Patients with Type 2 Diabetes Mellitus

Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update

Contact Info

Product

Resources

About